Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights

References

• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang Y-K, Yen C-J, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased αfetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Yau T, Kang Y-K, Kim T-Y, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564. doi:10.1001/jamaoncol.2020.4564
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952.
   PubMed Web of Science ®Google Scholar
• Alsina A, Kudo M, Vogel A, et al. Effects of subsequent systemic anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. Liver Cancer. 2020;9:93–104.
   PubMed Web of Science ®Google Scholar
• Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. J Hepatol. 2018;69(2):353–358.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Ryoo BY, Merle P, et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020;5:e000714.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;2022:EVIDoa2100070.
   Google Scholar
• Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008.
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193–202.
   PubMed Web of Science ®Google Scholar
• Qin S, Chen Z, Fang W, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study. ASCO Gastrointestinal Cancers Symposium; 2022.
   Google Scholar
• Qin S, Finn RS, Kudo M, et al. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol. 2019;15(16):1811–1822.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kudo M, Cheng A-L, et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study. J Clin Oncol. 2019;37(15_suppl):4152.
   Web of Science ®Google Scholar
• A study of nivolumab in combination with ipilimumab in participants with advanced hepatocellular carcinoma (CheckMate 9DW). Available from: https://ClinicalTrials.gov/. Accessed February 16, 2022.
   Google Scholar
• Llovet JM, Villanueva A, Marrero JA, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology. 2021;73(suppl_1):158–191.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517–3524.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a Phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–566.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19(5):682–693.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013;31(28):3509–3516.
   PubMed Web of Science ®Google Scholar
• El-Maraghi RH, Eisenhauer EA. Review of Phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in Phase III. J Clin Oncol. 2008;10:1346–1354.
   Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst. 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–e152.
   PubMed Web of Science ®Google Scholar
• Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541–3543.
   PubMed Web of Science ®Google Scholar
• Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol. 2018;58:125–135.
   PubMed Web of Science ®Google Scholar
• Rimola J, Da Fonseca LG, Sapena V, et al. Radiological response to nivolumab in patients with hepatocellular carcinoma: a multicenter analysis of real-life practice. Eur J Radiol. 2021;135:109484.
   PubMed Web of Science ®Google Scholar
• Manitz J, D’Angelo SP, Apolo AB, et al. Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. J Immunother Cancer. 2022;10:e003302.
   PubMed Web of Science ®Google Scholar
• Bruix J. Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: an unresolved Gordian knot. J Hepatol. 2021;74(6):1483–1488.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival. J Hepatol. 2019;70(6):1262–1277.
   PubMed Web of Science ®Google Scholar
• Kim C, Prasad V. Strength of validation for surrogate end points used in the US food and drug administration’s approval of oncology drugs. Mayo Clin Proc. 2016;91:713–725.
   Web of Science ®Google Scholar
• Carpenter D, Kesselheim AS, Joffe S. Reputation and precedent in the bevacizumab decision. N Engl J Med. 2011;365:e3.
   PubMed Web of Science ®Google Scholar
• Accelerated Approvals | FDA. CDER drug and biologic accelerated approvals based on a surrogate endpoint. Available from: https://www.fda.gov. Accessed April 23, 2022.
   Google Scholar
• News release. Bristol Myers Squibb. Bristol Myers Squibb statement on FDA advisory committee meeting on opdivo post-sorafenib hepatocellular carcinoma U.S. indication; 2021. Available from: https://bit.ly/2QBEfuY. Accessed April 27, 2022.
   Google Scholar
• Reig M, Darnell A, Forner A, et al. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis. 2014;34:444–455.
   PubMed Web of Science ®Google Scholar
• Reig M, Rimola J, Torres F, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology. 2013;58:2023–2031.
   PubMed Web of Science ®Google Scholar
• Reig M, Galle PR, Kudo M, et al. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int. 2021;41(3):598–607.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Morris MJ, Hodi FS, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012;104:1534–1541.
   PubMedGoogle Scholar
• Finn RS. Progression-free survival: starting point or endpoint in advanced HCC trial design? J Hepatol. 2019;70(6):1062–1064.
   PubMed Web of Science ®Google Scholar
• Song YH, Naumova AK, Liebhaber SA, Cooke NE. Physical and meiotic mapping of the region of human chromosome 4q11‐q13 encompassing the vitamin D binding protein DBP/Gc-globulin and albumin multigene cluster. Genome Res. 1999;9:581–587.
   PubMed Web of Science ®Google Scholar
• Ogden SK, Lee KC, Barton MC. Hepatitis B viral transactivator HBx alleviates p53-mediated repression of alpha-fetoprotein gene expression. J Biol Chem. 2000;275(36):27806–27814.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020;146(10):2439–2446.
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha‐fetoprotein levels. J Clin Gastroenterol. 2000;31:302–308.
   PubMed Web of Science ®Google Scholar
• Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67:727–38.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69:7385–7392.
   PubMed Web of Science ®Google Scholar
• Schraiber Ldos S, de Mattos AA, Zanotelli ML, et al. Alpha-fetoprotein level predicts recurrence after transplantation in hepatocellular carcinoma. Medicine. 2016;95:e2478.
   PubMed Web of Science ®Google Scholar
• Soong RS, Yu MC, Chan KM, et al. Analysis of the recurrence risk factors for the patients with hepatocellular carcinoma meeting University of California San Francisco criteria after curative hepatectomy. World J Surg Oncol. 2011;9:9.
   PubMed Web of Science ®Google Scholar
• He C, Zhang X, Li C, et al. Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization. Oncotarget. 2017;8:85599–85611.
   PubMedGoogle Scholar
• Tsai MC, Wang JH, Hung CH, et al. Favorable alpha‐fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2010;25:605–612.
   PubMed Web of Science ®Google Scholar
• Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha‐fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27:446–452.
   PubMed Web of Science ®Google Scholar
• Chen LT, Liu TW, Chao Y, et al. Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2005;22:217–226.
   PubMed Web of Science ®Google Scholar
• Fournier L, Ammari S, Thiam R, Cuenod CA. Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. Diagn Interv Imaging. 2014;95:689–703.
   PubMed Web of Science ®Google Scholar
• Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116:4590–4596.
   PubMed Web of Science ®Google Scholar
• Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha‐fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57:101–107.
   PubMed Web of Science ®Google Scholar
• Saeki I, Yamasaki T, Yamashita S, et al. Early predictors of objective response in patients with hepatocellular carcinoma undergoing lenvatinib treatment. Cancers. 2020;12(4):779.
   PubMed Web of Science ®Google Scholar
• Liu B, Shang X, Shi JY, et al. Early alpha-fetoprotein response is associated with survival in patients with HBV-related hepatocellular carcinoma receiving lenvatinib. Front Oncol. 2022;12:807189.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Dayyani F, Yen CJ, et al. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma. Clin Cancer Res. 2022. doi:10.1158/1078-0432.CCR-21-3275
   Web of Science ®Google Scholar
• Zhu AX, Finn RS, Kang YK, et al. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021;124(8):1388–1397.
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Merle P, et al. Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial. Ann Oncol. 2019;30(suppl_5):v253–v324.
   Google Scholar
• Kelley RK, Meyer T, Rimassa L, et al. Serum alpha-fetoprotein levels and clinical outcomes in the phase III CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2020;26(18):4795–4804.
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):424–432.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Montal R, Torres F, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol. 2017;66:1166–1172.
   PubMed Web of Science ®Google Scholar
• Meyer T, Palmer DH, Cheng A-L, et al. mRECIST to predict survival in advanced hepatocellular carcinoma: analysis of two randomized phase II trials comparing nintedanib vs sorafenib. Liver Int. 2017;37:1047–1055.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). J Clin Oncol. 2019;37(suppl_4):186.
   Web of Science ®Google Scholar
• Ducreux M, Zhu AX, Cheng AL, et al. IMbrave150: exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor). J Clin Oncol. 2021;39(suppl_15):4071.
   Web of Science ®Google Scholar
• Kudo M, Montal R, Finn RS, et al. Objective response predicts survival in advanced hepatocellular carcinoma treated with systemic therapies. Clin Cancer Res. 2021;28:1–9.
   Web of Science ®Google Scholar
• Kok PS, Cho D, Yoon WH, et al. Validation of progression-free survival rate at 6 months and objective response for estimating overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(9):e2011809.
   PubMed Web of Science ®Google Scholar
• Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet. 2021;398(10308):1359–1376.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–870.
   PubMed Web of Science ®Google Scholar
• Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1–2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015;5(5):e443–e449.
   PubMedGoogle Scholar
• Peng JK, Hepgul N, Higginson IJ, Gao W. Symptom prevalence and quality of life of patients with end-stage liver disease: a systematic review and meta-analysis. Palliat Med. 2019;33(1):24–36.
   PubMed Web of Science ®Google Scholar
• Durand F, Valla D. Assessment of the prognosis of cirrhosis: child-Pugh versus MELD. J Hepatol. 2005;42(Suppl 1):S100–S117.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558.
   PubMed Web of Science ®Google Scholar
• Fragaki M, Sifaki-Pistolla D, Orfanoudaki E, Kouroumalis E. Comparative evaluation of ALBI, MELD, and Child-Pugh scores in prognosis of cirrhosis: is ALBI the new alternative? Ann Gastroenterol. 2019;32(6):626–632.
   PubMed Web of Science ®Google Scholar
• Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. Lancet Oncol. 2017;18(2):e101–e112.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Personeni N, Czauderna C, et al. Systemic treatment of HCC in special populations. J Hepatol. 2021;74(4):931–943.
   PubMed Web of Science ®Google Scholar
• McNamara MG, Slagter AE, Nuttall C, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma - a meta-analysis. Eur J Cancer. 2018;105:1–9.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol. 2016;65:1140–1147.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Meyer T, Cheng AL, et al. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer. 2022;22(1):377.
   PubMed Web of Science ®Google Scholar
• Kudo M, Matilla A, Santoro A, et al. Checkmate-040: nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. J Clin Oncol. 2019;37(suppl_4):327.
   Web of Science ®Google Scholar
• D’Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatology. 2022. doi:10.1002/hep.32468
   Web of Science ®Google Scholar
• San-Chi C, Chao Y, Chen MH. Lenvatinib for the treatment of HCC: a single institute experience. J Clin Oncol. 2019;37(15_suppl):e15611.
   Web of Science ®Google Scholar
• Kuzuya T, Kawabe N, Hashimoto S, et al. Early changes in alpha-fetoprotein are a useful predictor of efficacy of atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma. Oncology. 2022;100(1):12–21.
   PubMed Web of Science ®Google Scholar
• Teufel M, Seidel H, Köchert K, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology. 2019;156(6):1731–1741.
   PubMed Web of Science ®Google Scholar
• Lee PC, Chao Y, Chen MH, et al. Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. Cancers. 2020;12(1):182.
   PubMed Web of Science ®Google Scholar
• Teng W, Lin -C-C, Ho -M-M, et al. Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. Am J Cancer Res. 2021;11(5):2319–2330.
   PubMed Web of Science ®Google Scholar
• Sangro B, Melero I, Wadhawan S, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73(6):1460–1469. doi:10.1016/j.jhep.2020.07.026
   PubMed Web of Science ®Google Scholar
• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–642. doi:10.1016/j.eururo.2016.08.002
   PubMed Web of Science ®Google Scholar
• Llovet JM, Peña CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(8):2290–2300. doi:10.1158/1078-0432.CCR-11-2175
   PubMed Web of Science ®Google Scholar
• Rimassa L, Kelley RK, Meyer T, et al. Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma. Liver Cancer. 2022;11(1):38–47. doi:10.1159/000519867
   PubMed Web of Science ®Google Scholar
• Finn RS, Kudo M, Cheng A-L, et al. Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study. Clin Cancer Res. 2021;27(17):4848–4858. doi:10.1158/1078-0432.CCR-20-4219
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol. 2013;58(1):169–177. doi:10.1016/j.jhep.2012.08.022
   PubMed Web of Science ®Google Scholar
• Chen BB, Shih TT. DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. World J Gastroenterol. 2014;20(12):3125–3134. doi:10.3748/wjg.v20.i12.3125
   PubMed Web of Science ®Google Scholar
• Lee JH, Park JY, Kim DY, et al. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int. 2011;31(8):1144–1149. doi:10.1111/j.1478-3231.2011.02541.x
   PubMed Web of Science ®Google Scholar
• Castello A, Rimassa L, Personeni N, et al. Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial. Mol Imaging Biol. 2020;22(5):1446–1454. doi:10.1007/s11307-020-01489-6
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Kobayashi M, Shindoh J, et al. 18F-fluorodeoxyglucose uptake in hepatocellular carcinoma as a useful predictor of an extremely rapid response to lenvatinib. Liver Cancer. 2020;9(1):84–92. doi:10.1159/000503577
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Kobayashi M, Shindoh J, et al. Pretreatment positron emission tomography with 18f-fluorodeoxyglucose may be a useful new predictor of early progressive disease following atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma. Oncology. 2021;99(10):611–621. doi:10.1159/000516565
   PubMed Web of Science ®Google Scholar
• Yao S, Ye Z, Wei Y, et al. Radiomics in hepatocellular carcinoma: a state-of-the-art review. World J Gastrointest Oncol. 2021;13(11):1599–1615. doi:10.4251/wjgo.v13.i11.1599
   PubMed Web of Science ®Google Scholar
• Liu F, Liu D, Wang K, et al. Deep learning radiomics based on contrast-enhanced ultrasound might optimize curative treatments for very-early or early-stage hepatocellular carcinoma patients. Liver Cancer. 2020;9(4):397–413. doi:10.1159/000505694
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208–218. doi:10.1016/S2468-1253(21)00427-1
   PubMed Web of Science ®Google Scholar
• Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219–229.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Cortellini A, Sukumaran A, et al. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer. 2021;21(1):301.
   PubMed Web of Science ®Google Scholar
• Chen VL, Xu D, Wicha MS, et al. Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review. Clin Gastroenterol Hepatol. 2020;18(13):2879–2902.
   PubMed Web of Science ®Google Scholar
• Ahn JC, Teng PC, Chen PJ, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021;73(1):422–436.
   PubMed Web of Science ®Google Scholar
• von Felden J, Craig AJ, Garcia-Lezana T, et al. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene. 2021;40(1):140–151.
   PubMed Web of Science ®Google Scholar